使用第二代抗肥胖药物。

Q3 Medicine

Diabetes Spectrum Pub Date : 2024-11-15 eCollection Date: 2024-01-01 DOI:10.2337/dsi24-0002

Sarah H Schmitz, Louis J Aronne

{"title":"使用第二代抗肥胖药物。","authors":"Sarah H Schmitz, Louis J Aronne","doi":"10.2337/dsi24-0002","DOIUrl":null,"url":null,"abstract":"Second-generation anti-obesity medications are more effective than their first-generation predecessors, resulting in an average weight loss of 15% when combined with lifestyle modifications. This article examines the efficacy and therapeutic implications of the three currently approved second-generation medications: setmelanotide for individuals with monogenic forms of obesity, semaglutide 2.4 mg, and tirzepatide. Particular emphasis is placed on the concurrent treatment of obesity and type 2 diabetes with semaglutide 2.4 mg and tirzepatide.","PeriodicalId":39737,"journal":{"name":"Diabetes Spectrum","volume":"37 4","pages":"303-312"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623031/pdf/","citationCount":"0","resultStr":"{\"title\":\"Using Second-Generation Anti-Obesity Medications.\",\"authors\":\"Sarah H Schmitz, Louis J Aronne\",\"doi\":\"10.2337/dsi24-0002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Second-generation anti-obesity medications are more effective than their first-generation predecessors, resulting in an average weight loss of 15% when combined with lifestyle modifications. This article examines the efficacy and therapeutic implications of the three currently approved second-generation medications: setmelanotide for individuals with monogenic forms of obesity, semaglutide 2.4 mg, and tirzepatide. Particular emphasis is placed on the concurrent treatment of obesity and type 2 diabetes with semaglutide 2.4 mg and tirzepatide.\",\"PeriodicalId\":39737,\"journal\":{\"name\":\"Diabetes Spectrum\",\"volume\":\"37 4\",\"pages\":\"303-312\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623031/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes Spectrum\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2337/dsi24-0002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Spectrum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2337/dsi24-0002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

第二代抗肥胖药物比第一代更有效，结合生活方式的改变，平均体重减轻15%。本文研究了目前批准的三种第二代药物的疗效和治疗意义：用于单基因肥胖个体的塞美拉肽、塞马鲁肽2.4 mg和替西帕肽。特别强调的是同时治疗肥胖和2型糖尿病的西马鲁肽2.4 mg和替西帕肽。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Using Second-Generation Anti-Obesity Medications.

Second-generation anti-obesity medications are more effective than their first-generation predecessors, resulting in an average weight loss of 15% when combined with lifestyle modifications. This article examines the efficacy and therapeutic implications of the three currently approved second-generation medications: setmelanotide for individuals with monogenic forms of obesity, semaglutide 2.4 mg, and tirzepatide. Particular emphasis is placed on the concurrent treatment of obesity and type 2 diabetes with semaglutide 2.4 mg and tirzepatide.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Diabetes Spectrum Medicine-Internal Medicine

CiteScore

2.70

自引率

0.00%

发文量

期刊介绍： The mission of Diabetes Spectrum: From Research to Practice is to assist health care professionals in the development of strategies to individualize treatment and diabetes self-management education for improved quality of life and diabetes control. These goals are achieved by presenting review as well as original, peer-reviewed articles on topics in clinical diabetes management, professional and patient education, nutrition, behavioral science and counseling, educational program development, and advocacy. In each issue, the FROM RESEARCH TO PRACTICE section explores, in depth, a diabetes care topic and provides practical application of current research findings.